23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › ADMA Biologics, Inc. › 2025-2026

ADMA Biologics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ADMA Biologics, Inc.’s Form 8-K, filed June 2, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 357Asset managers, any item
  • 1,753Fund votes
  • June 2, 2026Meeting date

Results at a glance

Meeting of June 2, 2026: 4 items on ADMA Biologics, Inc.’s Form 8-K, filed June 2, 2026: 4 passed (calculated).

Dissent

Notable dissent: 1 director (11.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 5.6%, as of September 30, 2026) · Caligan Partners (13F, 2.6%, as of September 30, 2026) · Nantahala Capital (13F, 1.2%, as of September 30, 2026)

Explore ADMA Biologics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by ADMA Biologics, Inc.

These tallies are ADMA Biologics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 2, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ADMA Biologics, Inc. — official shareholder meeting results, meeting held June 2, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Alison C. Finger 156,849,830---- 19,376,84223,040,875 89%Passed (calculated)—
Elect Director: Eduardo Rene Salas 171,947,523---- 4,279,14923,040,875 98%Passed (calculated)—
2. The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and 198,655,040329,056283,451 ---- 99.8%Passed (calculated)—
3. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay") 168,169,8667,730,690326,116 --23,040,875 96%Passed (calculated)—

Source: ADMA Biologics, Inc., Form 8-K, filed with the SEC on June 2, 2026 — read the filing on EDGAR.

How asset managers voted at the ADMA Biologics, Inc. 2025-2026 meeting

357 asset managers disclosed a vote on at least one ADMA Biologics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Alison C. Finger

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 156,849,830WITHHELD: 19,376,842
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Alison C. Finger

ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Alison C. Finger”): 156,849,830 for, 19,376,842 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 91,631,130 for, 10,396,856 withheld, 153 abstained.

FOR
FOR: 91,631,130ABSTAIN: 153WITHHOLD: 10,396,856
Largest asset managers voting on “To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or unt” at ADMA Biologics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock25,918,0100 0427,111For
Vanguard20,445,9360 15337,231For
Capital Group11,738,7610 00For
State Street8,946,8090 00For
Fidelity5,746,3390 00For
TIAA00 04,051,804Withhold
American Century3,547,2150 00For
Invesco2,561,0220 00For
Charles Schwab1,938,8070 00For
T. Rowe Price00 01,589,164Withhold
Nuveen00 01,439,853Withhold
Federated Hermes1,320,4570 00For
Dimensional1,299,9050 00For
Putnam00 01,167,273Withhold
Allspring688,5780 00For
Jackson National537,9810 00For
Equitable329,7280 0187,370Mixed
AIG/SunAmerica496,9380 00For
Bridge Builder Trust495,2790 00For
QUANTITATIVE MASTER SERIES LLC375,0730 00For
Columbia Threadneedle00 0364,267Withhold
World Funds Trust350,0000 00For
First Trust348,2230 00For
Russell Investments00 0292,066Withhold
Brighthouse75,2980 0202,333Mixed

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Elect Director: Eduardo Rene Salas

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 171,947,523WITHHELD: 4,279,149
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Eduardo Rene Salas

ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Eduardo Rene Salas”): 171,947,523 for, 4,279,149 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 99,796,742 for, 2,247,993 withheld, 39 abstained.

FOR
FOR: 99,796,742ABSTAIN: 39WITHHOLD: 2,247,993
Largest asset managers voting on “To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or unt” at ADMA Biologics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock26,345,1210 00For
Vanguard20,483,2810 390For
Capital Group11,738,7610 00For
State Street8,946,8090 00For
Fidelity5,746,3390 00For
TIAA4,051,8040 00For
American Century3,547,2150 00For
Invesco2,561,0220 00For
Charles Schwab1,938,8070 00For
T. Rowe Price00 01,589,164Withhold
Nuveen1,439,8530 00For
Federated Hermes1,320,4570 00For
Dimensional1,299,9050 00For
Putnam1,167,2730 00For
Allspring688,5780 00For
Jackson National537,9810 00For
Equitable329,7280 0187,370Mixed
AIG/SunAmerica496,9380 00For
Bridge Builder Trust495,2790 00For
QUANTITATIVE MASTER SERIES LLC375,0730 00For
Columbia Threadneedle364,2670 00For
World Funds Trust350,0000 00For
First Trust348,2230 00For
Russell Investments292,0660 00For
Brighthouse75,2980 0202,333Mixed

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 9 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 168,169,866AGAINST: 7,730,690

Prior year: 89.0% for (June 4, 2025 meeting) ▲ 6.6 pts

Details: description as filed, official tally, votes by 357 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

ADMA Biologics, Inc.’s own tally for this item (“3. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay")”): 168,169,866 for, 7,730,690 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 103 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at ADMA Biologics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock26,345,1210 00For
Vanguard20,483,29620 20For
Capital Group11,738,7610 00For
State Street8,946,8090 00For
Fidelity5,746,3390 00For
TIAA4,051,8040 00For
American Century3,547,2150 00For
Invesco02,561,022 00Against
Charles Schwab1,938,8070 00For
T. Rowe Price1,589,1640 00For
Nuveen1,439,8530 00For
Federated Hermes1,320,4570 00For
Dimensional1,299,9050 00For
Putnam1,167,2730 00For
Allspring688,5780 00For
Jackson National537,9810 00For
Equitable517,0980 00For
AIG/SunAmerica496,9380 00For
Bridge Builder Trust495,2790 00For
QUANTITATIVE MASTER SERIES LLC375,0730 00For
Columbia Threadneedle364,2670 00For
World Funds Trust350,0000 00For
First Trust348,2230 00For
Russell Investments292,0660 00For
Brighthouse277,6310 00For

Fund voting reports, all 103 managers: 99,153,394 for, 2,842,811 against, 48,567 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 282 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at ADMA Biologics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
State Street13,687,1810 00For
Capital Research Global Investors11,738,7610 00For
BlackRock9,326,7813,111 00For
Nuveen6,203,4770 00For
GEODE CAPITAL MANAGEMENT, LLC5,830,6050 00For
Caligan Partners LP4,109,8650 00For
American Century3,968,2590 00For
Invesco03,308,646 00Against
B Group, Inc.3,198,9490 00For
T. Rowe Price2,551,0270 00For
Charles Schwab2,089,7010 00For
Ranger Investment Management, L.P.2,055,6150 00For
Vanguard2,010,0520 00For
Northern Trust1,994,9170 00For
Federated Hermes1,848,7080 00For
Putnam1,802,4120 00For
Fundsmith LLP01,649,493 00Against
Duquesne Family Office LLC1,545,6100 00For
MELLON INVESTMENTS Corp1,501,8860 00For
Point721,490,6510 00For
PRINCIPAL GLOBAL INVESTORS1,392,6260 00For
MetLife Investment Management, LLC1,376,1290 00For
National Philanthropic Trust00 00Not Voted
JUPITER ASSET MANAGEMENT LTD924,1830 00For
Renaissance814,6020 00For

Institutional-manager reports, all 282 managers: 99,363,054 for, 6,072,612 against, 65,874 abstained, 1,199,338 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 198,655,040AGAINST: 329,056

Prior year: 99.9% for (June 4, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

ADMA Biologics, Inc.’s own tally for this item (“2. The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and”): 198,655,040 for, 329,056 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 101,996,205 for, 2 against, 48,567 abstained.

FOR
FOR: 101,996,205AGAINST: 2ABSTAIN: 48,567
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE F” at ADMA Biologics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock26,345,1210 00For
Vanguard20,483,3162 20For
Capital Group11,738,7610 00For
State Street8,946,8090 00For
Fidelity5,746,3390 00For
TIAA4,051,8040 00For
American Century3,547,2150 00For
Invesco2,561,0220 00For
Charles Schwab1,938,8070 00For
T. Rowe Price1,589,1640 00For
Nuveen1,439,8530 00For
Federated Hermes1,320,4570 00For
Dimensional1,299,9050 00For
Putnam1,167,2730 00For
Allspring688,5780 00For
Jackson National537,9810 00For
Equitable517,0980 00For
AIG/SunAmerica496,9380 00For
Bridge Builder Trust495,2790 00For
QUANTITATIVE MASTER SERIES LLC375,0730 00For
Columbia Threadneedle364,2670 00For
World Funds Trust350,0000 00For
First Trust348,2230 00For
Russell Investments292,0660 00For
Brighthouse277,6310 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Largest ADMA Biologics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 232,288,977 shares outstanding at the time of that meeting.

Fund voting reports: top ADMA Biologics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 11.34%
2Vanguard 8.82%
3Capital Group 5.05%
4State Street 3.85%
5Fidelity 2.47%
6TIAA 1.74%
7American Century 1.53%
8Invesco 1.10%
9Charles Schwab 0.83%
10T. Rowe Price 0.68%
Institutional-manager reports: top ADMA Biologics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1State Street 5.89%
2Capital Research Global Investors 5.05%
3BlackRock 4.02%
4Nuveen 2.67%
5GEODE CAPITAL MANAGEMENT, LLC 2.51%
6Caligan Partners LP 1.77%
7American Century 1.71%
8Invesco 1.42%
9B Group, Inc. 1.38%
10T. Rowe Price 1.10%

Reported ADMA Biologics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ADMA Biologics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock36,830,774 15.86%Form 13F, quarter ended March 31, 2026
Vanguard Group20,854,669 8.98%Form 13F, quarter ended March 31, 2026
State Street14,084,205 6.06%Form 13F, quarter ended March 31, 2026
Citadel Advisors6,247,242 2.69%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors5,005,481 2.15%Form 13F, quarter ended March 31, 2026
Invesco4,119,577 1.77%Form 13F, quarter ended March 31, 2026
Point723,309,657 1.42%Form 13F, quarter ended March 31, 2026
Goldman Sachs2,803,530 1.21%Form 13F, quarter ended March 31, 2026

Percentages above are of 232,288,977 shares outstanding, as reported by ADMA Biologics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ADMA Biologics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 357 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,753 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ADMA Biologics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 2, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADMA Biologics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ADMA Biologics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “ADMA Biologics (ADMA) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/adma-biologics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.